SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SNAP
SNAP 7.800+2.6%Oct 31 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biotech Jim who wrote (82)11/24/1999 3:59:00 PM
From: tommysdad   of 124
 
<<Do you know what therapeutic indication might be relevant for either a Y2 receptor agonist or antagonist? >>

Well, no. That's the problem, isn't it? Since NPY activates so many receptors (6, I believe, though Y6 may not be relevant in man), without a specific agonist or antagonist, it's going to be tough to figure that one out. And I am not aware of a Y2 knockout model. There is evidence that NPY itself has anti-epileptic properties, and the localization of NPY Y2 receptor suggests this activity is mediated through the Y2 receptor, but I don't believe the data are definitive.

So SNAP's guess at pain management is as good as any, I suppose. Hopefully, they have data they haven't published. Like a knock-out or a really good Y2 ligand.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News